Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,297,133
  • Shares Outstanding, K 58,170
  • Annual Sales, $ 264,730 K
  • Annual Income, $ -128,080 K
  • 60-Month Beta 2.07
  • Price/Sales 8.30
  • Price/Cash Flow N/A
  • Price/Book 6.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.64
  • Low Estimate -0.83
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -60.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.10 +17.48%
on 03/01/19
39.67 -4.94%
on 03/22/19
+4.77 (+14.48%)
since 02/22/19
3-Month
27.53 +36.98%
on 01/28/19
39.67 -4.94%
on 03/22/19
+7.48 (+24.74%)
since 12/21/18
52-Week
24.60 +53.29%
on 04/04/18
52.95 -28.78%
on 06/18/18
+5.71 (+17.84%)
since 03/22/18

Most Recent Stories

More News
Ptc Therapeutics Shares Up 20.3% Since SmarTrend's Buy Recommendation (PTCT)

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on February 22nd, 2019 at $32.16. In approximately 4 weeks, Ptc Therapeutics has returned 20.26% as of today's recent price of $38.67....

PTCT : 37.71 (-4.51%)
Watch for Ptc Therapeutics to Potentially Pullback After Gaining 1.46% Yesterday

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $34.91 to a high of $35.56. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high...

PTCT : 37.71 (-4.51%)
Research Report Identifies E*TRADE Financial, Kennedy-Wilson, Alteryx, PTC Therapeutics, Ocean Power Technologies, and NuVasive with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of E*TRADE Financial Corporation...

AYX : 81.97 (-4.32%)
PTCT : 37.71 (-4.51%)
OPTT : 4.42 (-4.54%)
NUVA : 56.00 (-1.20%)
ETFC : 45.02 (-3.39%)
KW : 20.68 (-4.04%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

PTCT : 37.71 (-4.51%)
PTC to Expand Product Portfolio in Latin America with WAYLIVRA(TM)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA(TM) by the Committee for Medicinal...

PTCT : 37.71 (-4.51%)
IONS : 78.90 (-1.99%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of 125,000 shares of its common stock to 20 new employees....

PTCT : 37.71 (-4.51%)
PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018.

PTCT : 37.71 (-4.51%)
PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019, has...

PTCT : 37.71 (-4.51%)
Acorda Therapeut is Among the Companies in the Biotechnology Industry with the Best Relative Performance (ACOR , SGMO , PTCT , CARA , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

PTCT : 37.71 (-4.51%)
SGMO : 8.89 (-9.29%)
ACOR : 13.13 (-6.55%)
MRTX : 73.23 (-2.81%)
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the...

PTCT : 37.71 (-4.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 40.37
1st Resistance Point 39.04
Last Price 37.71
1st Support Level 37.01
2nd Support Level 36.31

See More

52-Week High 52.95
Fibonacci 61.8% 42.12
Fibonacci 50% 38.78
Last Price 37.71
Fibonacci 38.2% 35.43
52-Week Low 24.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar